All News BiVictriX Therapeutics Plc

Equities

BVX

GB00BNXH3K91

Market Closed - London S.E. Other stock markets 11:35:28 2024-05-20 am EDT			5-day change	1st Jan Change
10 ^GBX	-13.04%		-13.04%	-4.76%

Apr. 17	Bivictrix granted FDA orphan drug status for rare cancer treatment	AN
Apr. 17	BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bivictrix granted FDA orphan drug status for rare cancer treatment	Apr. 17	AN
BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	Apr. 17	MT
Bivictrix Therapeutics plc Announces Resignation of Iain Ross from the Board	Dec. 05	CI
Bivictrix selects final sequences for lead tumour programme	Nov. 30	AN
BiVictriX Therapeutics plc Announces Pipeline Update on Lead Solid Tumour Programme, Bvx002	Nov. 30	CI
BiVictriX patent boost; 4Global deal extended	Nov. 15	AN
BiVictriX Obtains Japanese Patent for Acute Myeloid Leukemia Drug Conjugate	Nov. 15	MT
Bivictrix Therapeutics Says Patent Granted In Japan Providing Further Broad Protection For BVX001	Nov. 15	RE
Bivictrix says BVX001 increases survival rates by more than double	23-10-12	AN
BiVictriX Therapeutics' Blood Cancer Drug Delivers Extended Survival Rates in Trial	23-10-12	MT
Bivictrix Therapeutics PLC Extended Survival Rates Reported With Bvx001 In A Pre-Clinical Model Of Acute Myeloid Leukaemia	23-10-12	RE
BiVictriX Therapeutics appoints combined CFO/CBO to boost out-licensing efforts	23-10-06	AQ
Bivictrix hires new CFO as Alex Hughes steps down after seven months	23-10-03	AN
BiVictriX Therapeutics Appoints New CFO, Chief Business Officer	23-10-03	MT
BiVictriX Therapeutics Plc Announces Chief Financial Officer Changes	23-10-03	CI
BiVictriX Therapeutics Plc Appoints Adrian Howd as Chief Business Officer	23-10-03	CI
BiVictriX Therapeutics "looking really healthy" after positive first half	23-09-20	AQ
AEW UK REIT appoints new chair; Oberon raises money	23-09-19	AN
Earnings Flash (BVX.L) BIVICTRIX THERAPEUTICS Posts H1 Loss GBX-1.77	23-09-19	MT
BiVictriX Therapeutics Plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News BiVictriX Therapeutics Plc

Equities

BVX

GB00BNXH3K91

All News

Filters